June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
One-Year Results of a Phase 2 Clinical Trial Evaluating Resveratrol, Quercetin, and Curcumin (RQC) for the Treatment of Geographic Atrophy
Author Affiliations & Notes
  • Nicholas Pfahler
    Ophthalmology and Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States
  • Giedre Klovaite
    Ophthalmology and Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States
  • Stephanie Aman
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Zibute Zaparackas
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Paul A Knepper
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
    Ophthalmology and Visual Sciences, University of Illinois Chicago College of Medicine, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Nicholas Pfahler None; Giedre Klovaite None; Stephanie Aman None; Zibute Zaparackas None; Paul Knepper None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2266. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicholas Pfahler, Giedre Klovaite, Stephanie Aman, Zibute Zaparackas, Paul A Knepper; One-Year Results of a Phase 2 Clinical Trial Evaluating Resveratrol, Quercetin, and Curcumin (RQC) for the Treatment of Geographic Atrophy. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2266.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry age-related macular degeneration (AMD) is a retinal degenerative disease without known treatment. The advanced form of the disease is characterized by irreversible growth of geographic atrophy (GA) and corresponding loss of vision. Here we provide an initial analysis of an ongoing phase 2 study analyzing GA growth rate in participants taking oral antioxidants resveratrol, quercetin, and curcumin (RQC).

Methods : Participants were recruited from the office of Zaparackas & Knepper Ltd. In Chicago, Illinois (n=12). All participants took oral RQC daily and completed one year of follow-up. GA area was measured manually using OCT autofluorescent images taken at baseline, 3 months, 6 months, and 1 year. Measurements were made in mm2 and adjusted using square root transformation (mm) to account for variation in baseline lesion size. The annual GA growth rate of subjects taking RQC was calculated as the change in area (mm2 or mm) per year and compared with the expected growth rate of untreated subjects based on a meta-analysis of natural history studies by Wang et al. (2021).

Results : The mean geographic atrophy area increased from 1.48 mm2 ± 1.85 mm2 (1.05 ± 0.65 mm) at baseline to 1.84 ± 2.18 mm2 (1.17 ±0.71 mm) after 12 months. The mean annual growth rate was 0.35 ± 0.35 mm2/year (0.12 ± 0.07 mm/year). The growth rate of participants taking RQC was significantly lower than untreated subjects both before (p=0.0004) and after (p<0.0001) square root transformation.

Conclusions : Advanced dry AMD patients taking oral RQC had a low GA growth rate compared with untreated subjects. These results support our previous phase 1 results and suggest that RQC may be a promising oral therapy for patients with advanced dry AMD.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Fig. 1 shows the expected growth of GA based on a meta-analysis of natural history studies (dashed line) compared with GA growth in subjects taking RQC (solid line). (A) shows GA growth as volume in mm3 (B) shows GA growth as volume in square root-adjusted mm.

Fig. 1 shows the expected growth of GA based on a meta-analysis of natural history studies (dashed line) compared with GA growth in subjects taking RQC (solid line). (A) shows GA growth as volume in mm3 (B) shows GA growth as volume in square root-adjusted mm.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×